Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA

Eight-Week Hepatitis C Treatment with New Direct Acting Antivirals Has a Better Safety Profile While Being Effective in the Treatment-Naïve Geriatric Population Without Liver Cirrhosis and Hepatitis C Virus-RNA < 6 Million IU/mL

Published:2018-09-27 Issue:12 Volume:63 Page:3480-3486
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Yanny Beshoy,Saab Sammy,Durazo Francisco,Latt Nyan,Mitry Amanda,Mikhail Mira Moris,Hanna Ramy M.,Aziz Antony,Sahota Amandeep

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/article/10.1007/s10620-018-5283-1/fulltext.html

Reference35 articles.

1. Saab S, Park SH, Mizokami M, Omata M, Mangia A. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Hepatology. 2016;63:1112–1119.

2. Latt N, Yanny B, Gharibian D, Gevorkyan R, Sahota A. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety. World J Gastroenterol. 2017;23:4759–4766.

3. Ahmed B, Nanji K, Mujeeb R, Patel MJ. Effects of polypharmacy on adverse drug reactions among geriatric outpatients at a tertiary care hospital in Karachi: a prospective cohort study. PLoS ONE. 2014;9:e112133.

4. Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364:2429–2438.

5. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293–300.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial);PLOS ONE;2023-05-18

2. Real-World Therapeutic Outcomes of Direct-Acting Antiviral Regimens and Formidable Challenges;Hepatitis C Virus-Host Interactions and Therapeutics: Current Insights and Future Perspectives;2023-01

3. Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis;Annals of Translational Medicine;2021-05

4. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions;World Journal of Gastroenterology;2019-08-07